AffiliationDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester
MetadataShow full item record
AbstractDespite the highly immunogenic potential of small cell lung cancer (SCLC), progress in evaluating the therapeutic value of immune checkpoint agents has lagged behind that of non-small cell lung cancer. Results from a number of phase I-III clinical trials that specifically address the use of anti-PD-1, anti-PD-L1 and anti-CTLA-4 agents in SCLC have now been reported. This review will focus on the available evidence for immune checkpoint blockade in SCLC and review current biomarker strategies with the aim of providing perspective and interpretation of this data for clinical practice.
CitationTay RY, Heigener D, Reck M, Califano R. Immune checkpoint blockade in small cell lung cancer. Lung Cancer. 2019 Aug 22;137:31-7.
- PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
- Authors: Tanvetyanon T, Gray JE, Antonia SJ
- Issue date: 2017 Mar
- The next generation of immunotherapy: keeping lung cancer in check.
- Authors: Somasundaram A, Burns TF
- Issue date: 2017 Apr 24
- Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
- Authors: Konala VM, Madhira BR, Ashraf S, Graziano S
- Issue date: 2020
- Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
- Authors: Hayashi H, Nakagawa K
- Issue date: 2020 May
- Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer.
- Authors: Lim SW, Ahn MJ
- Issue date: 2019 Jan